Amyloid Unmasked: A Rare Case of Apolipoprotein A- IV Cardiac Amyloidosis
We present a rare case of apolipoprotein A-IV cardiac amyloidosis. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , G. Fishbein, J. Theis, E. PcPhail, D. Cruz Source Type: research
Heart Transplantation for Cardiac Amyloidosis: The Road Less Traveled
We present a case of AL-CA who underwent chemotherapy and ASCT before HT. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M. Psotka, A. Rollins, V. Khangoora, P. Shah, J. Kennedy Source Type: research
Human Myocardial Mitochondrial Function is Impaired in Cardiac Light Chain Amyloidosis but Not in Transthyretin Amyloidosis
Purpose: Cardiac amyloidosis is a common cause of heart failure with preserved ejection fraction and increasingly recognized since new diagnostic algorithms and therapeutic approaches were established during recent years. Mitochondrial dysfunction is known to play a key role in different etiologies of human heart failure but its role in cardiac amyloidosis remains unclear. Here we investigated myocardial mitochondrial function in endomyocardial biopsies from humans with different types of cardiac amyloidosis. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , E. Zweck, F. Nienhaus, D. Oehler, H. Schultheiss, M. Roden, M. Kelm, J. Szendroedi, A. Polzin, D. Scheiber Source Type: research
Real life experience of tafamidis for the treatment of Spanish patients with Val30Met transthyretin amyloidosis with polyneuropathy
CONCLUSIONS: Our results reinforce the tafamidis efficacy to treat A-ATTRv-PNP if started early in the disease course. Patients with the V30M variant, NIS<15 and PND I are the most appropriate subjects for this treatment.PMID:38556397 | DOI:10.1016/j.medcli.2024.01.008 (Source: Medicina Clinica)
Source: Medicina Clinica - March 31, 2024 Category: General Medicine Authors: Maria Antonia Ribot Sanso Adri án Rodriguez Rodriguez Laura Mart ínez Vicente Teresa Sevilla Cristina Borrachero Garro Julian Fern ández Martín Adri án Antón Vicente Moises Morales de la Prida Luc ía Galán Dávila Laura Gonz ález Vázquez Ferran Source Type: research
A Case of Immunoglobulin Light Chain Hepatic Amyloidosis with Abdominal Hematoma
(Source: Digestive Diseases and Sciences)
Source: Digestive Diseases and Sciences - March 30, 2024 Category: Gastroenterology Source Type: research
Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study
Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2024.285145. Online ahead of print.ABSTRACTNot available.PMID:38546676 | DOI:10.3324/haematol.2024.285145 (Source: Haematologica)
Source: Haematologica - March 28, 2024 Category: Hematology Authors: Kai-Ni Shen Ya-Juan Gao Long Chang Lu Zhang Xin-Xin Cao Zhuang Tian Yi-Ning Wang Dao-Bin Zhou Jian Li Source Type: research
Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study
CONCLUSIONS: This analysis suggests that patisiran is well tolerated and may provide a substantial clinical benefit for Taiwanese patients with hATTR amyloidosis with polyneuropathy.TRIAL REGISTRATION INFORMATION: The studies were registered on the ClinicalTrials.gov. The APOLLO study ClinicalTrials.gov identifier is NCT01960348 (https://clinicaltrials.gov/ct2/show/NCT01960348), with the registration date of October 10, 2013, and the first patient was enrolled on December 13, 2013. For the global OLE, the ClinicalTrials.gov identifier is NCT02510261 (https://clinicaltrials.gov/ct2/show/NCT02510261) with the registration da...
Source: J Formos Med Assoc - March 28, 2024 Category: General Medicine Authors: Kon-Ping Lin Chih-Chao Yang Yi-Chung Lee Ming-Jen Lee John Vest Marianne T Sweetser Matthew T White Prajakta Badri Sung-Tsang Hsieh Chi-Chao Chao Source Type: research
Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study
Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2024.285145. Online ahead of print.ABSTRACTNot available.PMID:38546676 | DOI:10.3324/haematol.2024.285145 (Source: Haematologica)
Source: Haematologica - March 28, 2024 Category: Hematology Authors: Kai-Ni Shen Ya-Juan Gao Long Chang Lu Zhang Xin-Xin Cao Zhuang Tian Yi-Ning Wang Dao-Bin Zhou Jian Li Source Type: research
Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study
CONCLUSIONS: This analysis suggests that patisiran is well tolerated and may provide a substantial clinical benefit for Taiwanese patients with hATTR amyloidosis with polyneuropathy.TRIAL REGISTRATION INFORMATION: The studies were registered on the ClinicalTrials.gov. The APOLLO study ClinicalTrials.gov identifier is NCT01960348 (https://clinicaltrials.gov/ct2/show/NCT01960348), with the registration date of October 10, 2013, and the first patient was enrolled on December 13, 2013. For the global OLE, the ClinicalTrials.gov identifier is NCT02510261 (https://clinicaltrials.gov/ct2/show/NCT02510261) with the registration da...
Source: J Formos Med Assoc - March 28, 2024 Category: General Medicine Authors: Kon-Ping Lin Chih-Chao Yang Yi-Chung Lee Ming-Jen Lee John Vest Marianne T Sweetser Matthew T White Prajakta Badri Sung-Tsang Hsieh Chi-Chao Chao Source Type: research
Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study
Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2024.285145. Online ahead of print.ABSTRACTNot available.PMID:38546676 | DOI:10.3324/haematol.2024.285145 (Source: Haematologica)
Source: Haematologica - March 28, 2024 Category: Hematology Authors: Kai-Ni Shen Ya-Juan Gao Long Chang Lu Zhang Xin-Xin Cao Zhuang Tian Yi-Ning Wang Dao-Bin Zhou Jian Li Source Type: research
Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study
Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2024.285145. Online ahead of print.ABSTRACTNot available.PMID:38546676 | DOI:10.3324/haematol.2024.285145 (Source: Haematologica)
Source: Haematologica - March 28, 2024 Category: Hematology Authors: Kai-Ni Shen Ya-Juan Gao Long Chang Lu Zhang Xin-Xin Cao Zhuang Tian Yi-Ning Wang Dao-Bin Zhou Jian Li Source Type: research
